Alkermes Shares Rise on Positive Phase 1b Results for ALKS 7290
Alkermes (ALKS) reported positive phase 1b results for its experimental ADHD drug, ALKS 7290. The orexin 2 receptor agonist showed promising performance in a proof-of-concept study and was well tolerated by participants. These findings have led to an approximate 7% rise in the company's stock price during premarket trading on Monday. ALKS 7290 is being developed as a novel treatment for attention deficit hyperactivity disorder (ADHD). The phase 1b trial evaluated both safety and efficacy, with results indicating that it met key endpoints. Positive early-stage data often drive investor optimism in the biopharmaceutical sector due to their potential implications for future clinical development. The market reaction highlights confidence in Alkermes' pipeline progress. While further trials are needed before regulatory approval can be sought, these initial findings represent a significant step forward and could attract interest from pharmaceutical partners or investors.
Tickers: $ALKS